Heart failure (HF) ranks among the most costly chronic diseases in developed countries. At
present these countries devote 1–2% of all healthcare expenditures towards HF. In the US …

Acute heart failure syndromes (AHFS) remain a major cause of morbidity and mortality, in
part because the development of new therapies for these disorders has been marked by …

Background: A low-sodium diet is an accepted treatment of patients with heart failure (HF),
although minimal evidence exists on the appropriate amount of sodium intake for this …

Abstract Aims Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator. This
study evaluated the haemodynamic effect and safety of cinaciguat added to standard …

BACKGROUND: Relaxin is upregulated in human heart failure (HF). Animal and clinical
data suggest beneficial hemodynamic and renal effects from vasodilation. We determined …

Aims Thrombin is a critical element of crosstalk between pathways contributing to worsening
of established heart failure (HF). The aim of this study is to explore the efficacy and safety of …

Background—Cinaciguat (BAY 58–2667) is the first of a new class of soluble guanylate
cyclase activators in clinical development for acute decompensated heart failure. We aimed …

Background Around 50% of hospital readmissions due to heart failure are preventable, with
lack of adherence to prescribed self-care as a driving factor. Remote tracking and reminders …

Intravenous diuretics are the cornerstone of management for patients hospitalized for heart
failure. Physiologic data suggest that intermittent high-dose furosemide promotes …

Acute myocardial infarction is one of the 10 leading reasons for admission to adult critical
care units. In-hospital mortality for this condition has remained static in recent years, and this …